Explore 3 Stock Ideas & Industry Insights Download Free Report

18889881171
Shopping Cart 0
countryflagUS
Login

Tenaya Therapeutics Inc

Healthcare US TNYA

0.68USD
-0.0387(5.38%)

Last update at 2026-06-16T20:27:00Z

Day Range

0.680.72
LowHigh

52 Week Range

1.668.09
LowHigh

Fundamentals

  • Previous Close 0.72
  • Market Cap361.18M
  • Volume3436064
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-122.52000M
  • Revenue TTM0.00000M
  • Revenue Per Share TTM-
  • Gross Profit TTM 0.00000M
  • Diluted EPS TTM-1.65

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Income before tax -123.66500M -72.72100M -38.39500M -26.23100M
Minority interest - - - -
Net income -123.66304M -69.65200M -38.30800M -25.77800M
Selling general administrative 31.08M 18.41M 7.81M 4.56M
Selling and marketing expenses - - - -
Gross profit - - - -
Reconciled depreciation 6.47M 2.96M 2.48M 1.99M
Ebit -132.08800M -75.76700M -38.91200M -27.71200M
Ebitda -125.62100M -72.80600M -36.42900M -25.72300M
Depreciation and amortization 6.47M 2.96M 2.48M 1.99M
Non operating income net other 1.96M 0.09M - -
Operating income -125.62100M -72.80600M -38.91200M -27.71200M
Other operating expenses 125.62M 72.81M 38.91M 27.71M
Interest expense -0.00196M 72.73M 0.00000M 0.00000M
Tax provision 0.00000M 0.00000M 0.00000M 0.00000M
Interest income 1.95M 0.11M 0.09M 0.45M
Net interest income 1.95M 0.11M 0.09M 0.45M
Extraordinary items - - - -
Non recurring - - - -
Other items - - - -
Income tax expense -0.00196M -3.06900M -0.08700M -0.45300M
Total revenue 0.00000M 0.00000M 0.00000M 0.00000M
Total operating expenses 125.62M 72.81M 38.91M 27.71M
Cost of revenue - - - -
Total other income expense net 1.96M 0.09M 0.52M 1.48M
Discontinued operations - - - -
Net income from continuing ops -123.66500M -72.72100M -38.39500M -26.23100M
Net income applicable to common shares -123.66500M -72.72100M -38.39500M -26.23100M
Preferred stock and other adjustments - - - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 170.51M 278.94M 314.19M 148.16M 38.00M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets 6.94M 7.23M 4.06M 1.43M 1.12M
Total liab 31.09M 278.94M 35.66M 229.48M 81.74M
Total stockholder equity 139.42M 243.38M 278.53M -81.31500M -43.73900M
Deferred long term liab - - - - -
Other current liab 12.78M 10.66M 0.16M 4.02M 3.52M
Common stock 0.00700M 0.00700M 0.00400M 0.00100M 0.00100M
Capital stock 0.00700M 0.00700M 0.00400M 0.00000M 0.00000M
Retained earnings -403.28200M -279.19800M -155.53300M -82.81200M -44.41700M
Other liab - 0.23M 0.18M 3.68M 4.58M
Good will - - - - -
Other assets 0.00000M 4.79M 4.13M 1.01M 0.68M
Cash 45.68M 95.27M 38.13M 128.53M 23.87M
Cash and equivalents - - - - -
Total current liabilities 22.73M 24.25M 21.77M 5.04M 4.12M
Current deferred revenue - - 8.90M - -
Net debt -33.25700M -80.17300M -24.42200M -128.53500M -23.87200M
Short term debt 4.32M 4.01M 1.99M - -
Short long term debt - - - - -
Short long term debt total 12.42M 15.10M 13.71M - -
Other stockholder equity 542.80M 522.95M 120.01M 1.50M 0.68M
Property plant equipment - 51.03M 43.02M 17.18M 9.57M
Total current assets 111.58M 193.75M 255.36M 129.96M 27.74M
Long term investments 0.00000M 17.70M - - -
Net tangible assets - 243.38M 278.53M -81.31500M -43.73900M
Short term investments 58.96M 91.25M 213.17M 0.00000M 2.75M
Net receivables - - - - -
Long term debt - - - - -
Inventory - - - - -
Accounts payable 5.63M 9.58M 10.72M 1.02M 0.60M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income -0.10600M -0.37800M -0.14100M - -
Additional paid in capital - - - - -
Common stock total equity - 0.00700M 0.00400M - -
Preferred stock total equity - - - - -
Retained earnings total equity - -279.19800M -155.53300M - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 4.99M 4.79M 4.13M 1.01M 0.68M
Deferred long term asset charges - - - - -
Non current assets total 58.93M 85.19M 58.83M 18.20M 10.26M
Capital lease obligations 12.42M 15.10M 15.70M - -
Long term debt total - - - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Investments 104.27M -213.44300M 2.75M -2.65700M
Change to liabilities 6.01M 12.06M 0.14M 0.40M
Total cashflows from investing activities 83.65M -238.56400M -7.01000M -5.58300M
Net borrowings - - - -
Total cash from financing activities 77.77M 208.97M 147.27M 30.51M
Change to operating activities -2.50900M -3.85800M -0.37600M -0.64700M
Net income -123.66500M -72.72100M -38.39500M -26.23100M
Change in cash 56.99M -90.40600M 104.81M 0.83M
Begin period cash flow 38.68M 129.08M 24.27M 23.44M
End period cash flow 95.67M 38.68M 129.08M 24.27M
Total cash from operating activities -104.42400M -60.81200M -35.44700M -24.09600M
Issuance of capital stock 77.39M 208.52M 147.24M 30.45M
Depreciation 6.47M 2.96M 2.48M 1.99M
Other cashflows from investing activities 0.00800M 0.00800M 0.00800M 0.00800M
Dividends paid - - - -
Change to inventory - - - -
Change to account receivables - - - -
Sale purchase of stock 77.77M -0.01300M -0.00100M -0.00300M
Other cashflows from financing activities 0.38M 20.44M 147.27M 30.51M
Change to netincome 11.68M 3.01M 0.70M 0.40M
Capital expenditures 20.63M 25.12M 9.76M 2.93M
Change receivables - - - -
Cash flows other operating -4.61000M -6.25200M - -
Exchange rate changes - - - -
Cash and cash equivalents changes 56.99M -90.40600M - -
Change in working capital -0.84900M 4.74M -0.23400M -0.25000M
Stock based compensation 11.47M 2.95M 0.74M 0.41M
Other non cash items 2.16M 1.06M -0.07500M 0.06M
Free cash flow -125.05400M -85.93300M -45.21000M -27.02200M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to EBITDA (x)
TNYA
Tenaya Therapeutics Inc		 -0.0387 5.38% 0.68 - - - 2.41 -0.6742
NVO
Novo Nordisk A/S		 -0.37 0.84% 43.55 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 0.0012 0.0027% 44.87 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 2.71 0.60% 453.17 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 -0.25 0.04% 614.73 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

Tenaya Therapeutics, Inc., a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through gene editing, cellular regeneration, and gene addition. The company is developing TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy which is in phase 1 clinical trial; TN-301, a small molecule for heart failure with preserved ejection fraction which is in phase 1 clinical trial; and TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy which is in preclinical stage. It also develops an adeno-associated virus-based gene therapy designed to deliver the dworf gene for patient with dilated cardiomyopathy; and reprogramming program for heart failure due to prior myocardial infarction. Tenaya Therapeutics, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.

Tenaya Therapeutics Inc

171 Oyster Point Boulevard, South San Francisco, CA, United States, 94080

Key Executives

Name Title Year Born
Mr. Faraz Ali M.B.A. CEO, Sec. & Director 1973
Dr. Deepak Srivastava M.D. Scientific Founder, Chairman of Scientific Advisory Board & Director 1967
Ms. Leone D. Patterson M.B.A. Chief Financial & Bus. Officer 1963
Dr. Whittemore G. Tingley M.D., PH.D. Chief Medical Officer 1968
Dr. Eric N. Olson Ph.D. Scientific Founder & Member of Scientific Advisory Board NA
Dr. Bruce R. Conklin Scientific Founder NA
Dr. Saptarsi Haldar M.D. Scientific Founder NA
Dr. Sheng Ding Scientific Founder NA
Dr. Benoit G. Bruneau Ph.D. Scientific Founder NA
Dr. Kee-Hong Kim Ph.D. Chief Technology Officer 1966

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.